SINGAPORE, 15 June 2016 – Raman Singh, President, Mundipharma Asia Pacific, Latin America, the Middle East and Africa, has been ranked the world’s fourth most influential person in the pharmaceutical industry by the UK’s Medicine Maker. This comes after Mundipharma achieved year-on-year growth of 79%, expanded its business hub in Singapore and begun construction of a R&D and manufacturing facility in the city-state.
Mr Singh was among only two executives from the private sector, and the only Asian-based person, to be ranked within the top five.
The Medicine Maker’s Power List ranks the top 100 most influential people in the global pharmaceutical industry who inspire change by solving business problems, founding research and championing causes. It includes top executives, academics and other professionals from leading companies and prestigious institutions around the world.
Mr Singh said: “Being named in this list is a reflection of the hard work put in across the whole company over a great year, and our vision for the future. Mundipharma is dedicated to ensuring that the emerging world has equal access to innovation as more mature Western economies.”
Earlier this year Mundipharma held a groundbreaking ceremony for its new R&D and manufacturing facility, which will serve emerging markets. It has also recently expanded its head office in another demonstration of the company’s commitment to Singapore, the region and the emerging world.
Mundipharma’s 79% growth over the last year is the latest milestone in a continuous upward growth trajectory since Mr Singh joined Mundipharma in 2011. Total growth over that period stands at 459%.
People on Medicine Maker Power List were evaluated and ranked by each individual judge on the judging panel. The rankings were then averaged to obtain the final Power List.
For further information please contact:
Head of Communications & Digital Strategy –
Asia Pacific, Middle East, Africa & Latin America
+65-6303-9732 | email@example.com
Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and antiseptics.
For more information please visit: www.mundipharma.com.sgTags: press releases